NCT05510427View on ClinicalTrials.gov

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 7, 2023

Primary Completion Date

August 7, 2023

Study Completion Date

August 7, 2023

Conditions
CholangiocarcinomaLiver Cancer
Interventions
DRUG

Infigratinib

Given by PO

DRUG

Atezolizumab

Given by (IV) vein

DRUG

Bevacizumab

Given by (IV) vein

Sponsors

Collaborators (1)

Helsinn Healthcare SA
All Listed Sponsors
collaborator

Helsinn Healthcare SA

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER